FDA Highlights Systemic Issues at Mylan Laboratories in Recent Warning
FDA warns Mylan Laboratories for critical cGMP violations in quality control, data integrity, and governance, urging urgent corrective actions to ensure compliance.
FDA Warning Letter: MedOffice Saglik Endustri Anonim Sirketi
he FDA inspection at MedOffice Saglik Endustri Anonim Sirketi revealed significant CGMP violations that could jeopardize product quality and consumer safety. Issues ranged from inadequate testing of drug products to…
Corrective and Prevention Action (CAPA) Plan in GMP
Explore CAPA's role in GMP for pharmaceuticals: key processes, challenges, and strategies for regulatory compliance